文献速递临床试验与 GCP

氯胺酮联合硫酸镁治疗神经病理性疼痛:随机对照试验方案

Effect of ketamine combined with magnesium sulfate in neuropathic pain patients (KETAPAIN): study protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2017-11-03

本研究为在法国克莱蒙费朗大学医院开展的随机、双盲、交叉、安慰剂对照试验方案,拟纳入22例难治性神经病理性疼痛患者,比较静脉氯胺酮联合或不联合硫酸镁与安慰剂的疗效。主要终点为5周内0-10数字疼痛评分量表疼痛强度的曲线下面积(AUC),按意向性治疗分析。鉴于现有药物疗效有限,作者认为氯胺酮联合或不联合硫酸镁可能是有待标准化的治疗选择。

要点

  • 拟纳入22例难治性神经病理性疼痛患者,采用随机双盲交叉安慰剂对照设计。
  • 静脉氯胺酮/安慰剂、氯胺酮/硫酸镁、安慰剂/安慰剂按随机顺序每5周给药一次。
  • 主要终点为5周内0-10数字疼痛评分量表疼痛强度的曲线下面积(AUC)。

核心结论

  • 鉴于现有神经病理性疼痛药物疗效有限,氯胺酮联合或不联合硫酸镁可能是有待标准化的治疗选择。

研究设计与样本

  • 随机、双盲、交叉、安慰剂对照研究,在法国克莱蒙费朗大学医院开展,拟纳入22例神经病理性疼痛患者。

关键数值与推荐

  • 主要终点为5周内0-10数字疼痛评分量表评估的疼痛强度曲线下面积(AUC)。
  • 静脉氯胺酮/安慰剂、氯胺酮/硫酸镁、安慰剂/安慰剂按随机顺序给予每例患者,每5周一次。
  • 数据分析按意向性治疗进行,除主要分析外所有统计检验采用α风险5%(双侧)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Neuropathic pain is difficult to treat, and the efficacy of recommended drugs remains limited. N-methyl-D-aspartate receptors are implicated, and antagonists are a pharmacological option. Ketamine is widely used in French pain clinics, but without consensus or recommendations. Furthermore, the association of ketamine with magnesium has been poorly studied. The aim of the present study is to evaluate the benefit of ketamine with or without magnesium in refractory neuropathic pain. METHODS/DESIGN: A randomized, double-blind, crossover, placebo-controlled study will be performed in Clermont-Ferrand University Hospital, Clermont-Ferrand, France. The aim is to evaluate the effect of ketamine with or without magnesium in 22 patients with neuropathic pain. Intravenous ketamine/placebo, ketamine/magnesium sulfate, or placebo/placebo will be administered consecutively to each patient, in random order, once at 5-week intervals. The primary endpoint is the AUC of pain intensity assessed on a 0-10 Numeric Pain Rating Scale for a 5-week period. Data analysis will be performed on an intention-to-treat basis, and all statistical tests (except primary analysis) will be performed with an α risk of 5% (two-sided). DISCUSSION: Considering the poor efficacy of the drugs available for neuropathic pain, ketamine with or without magnesium sulfate may be a valuable therapeutic option that needs to be standardized. TRIAL REGISTRATION: EudraCT number- 2015-000142-29 . Registered on April 9, 2015; version 1.4.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Delage N, Morel V, Picard P, et al. Effect of ketamine combined with magnesium sulfate in neuropathic pain patients (KETAPAIN): study protocol for a randomized controlled trial. Trials. 2017. PMID: 29100524. doi:10.1186/s13063-017-2254-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。